Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.
暂无分享,去创建一个
H. Nomura | J. Hayashi | N. Furusyo | M. Nakamuta | E. Ogawa | Kazuhiro Takahashi | K. Dohmen | Masaki Kato | N. Higashi | T. Satoh | A. Kawano | S. Shimoda | E. Kajiwara | T. Koyanagi | K. Azuma